PBAC Public Summary Documents – July 2022

Page last updated: 27 October 2023

Public Summary Documents relating to the July 2022 PBAC meeting.

• Adalimumab: Injection 40 mg in 0.4 mL pre-filled pen, Injection 40 mg in 0.4 mL pre-filled syringe; Yuflyma®
• Apalutamide: Tablet 60 mg; Erlyand®
• Anifrolumab: Solution concentrate for I.V. infusion 300 mg in 2 mL; Saphnelo®
• Asciminib: Tablet 20 mg, Tablet 40 mg; Scemblix®
• Atezolizumab: Solution concentrate for I.V. infusion 840 mg in 14 mL, Solution concentrate for I.V. infusion 1200 mg in 20 mL; Tecentriq®
• Azacitidine: Tablet 200 mg, Tablet 300 mg; Onureg®
• Beclometasone with formoterol: Pressurised inhalation containing beclometasone dipropionate 200 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 doses; Fostair®
• Cannabidiol: Oral liquid 100 mg per mL, 100 mL; Epidyolex®
• Dupilumab: Injection 200 mg in 1.14 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled syringe; Dupixent®
• Eptinezumab: Solution concentrate for I.V infusion 100 mg in 1 mL; Vyepti®
• Esketamine: Nasal spray solution 28 mg in 0.2 mL; Spravato®
• Evolocumab: Injection 140 mg in 1 mL single use pre-filled pen, Injection 420 mg in 3.5 mL single use pre-filled cartridge; Repatha®
• Finerenone: Tablet 10 mg, Tablet 20 mg; Kerendia®
• Human menopausal gonadotrophin: Injection 600 I.U. in 0.96 mL pre-filled multi-dose pen, Injection 1200 I.U. in 1.92 mL pre-filled multi-dose pen; Menopur®
• Leuprorelin acetate: Suspension for subcutaneous injection (modified release) containing 45 mg of leuprorelin acetate; Eligard® 6 month

• Midazolam: Oromucosal solution in pre-filled syringe 2.5 mg in 0.25 mL, Oromucosal solution in pre-filled syringe 5 mg in 0.5 mL, Oromucosal solution in pre-filled syringe 7.5 mg in 0.75 mL, Oromucosal solution in pre-filled syringe 10 mg in 1 mL; Zyamis®

• Natalizumab: Solution concentrate for I.V. infusion 300 mg in 15 mL; Tysabri®
• Nivolumab (urothelial carcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL: Opdivo®
• Nivolumab(oesophageal carcinoma or gastroesophageal junction carcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
• Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza®
• Pegcetacoplan: Solution for subcutaneous infusion 1,080 mg in 20 mL; Empaveli™
• Pegvaliase: Solution for injection 2.5 mg in 0.5 mL, Solution for injection 10 mg in 0.5 mL, Solution for injection 20 mg in 1 mL; Palynziq®
• Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
• Polyethylene glycol 400 with propylene glycol: Eye drops 4 mg-3 mg per mL, 15 mL; Optix®
• Progesterone: Pessary 400 mg; Cyclogest®
• Relatlimab with nivolumab: Injection concentrate for I.V. infusion containing 80 mg relatlimab and 240 mg nivolumab in 20 mL; Opdualag®
• Risankizumab: Solution concentrate for I.V. infusion 600 mg in 10 mL, Injection 360 mg in 2.4 mL in pre-filled cartridge; Skyrizi® - November 2022
• Romosozumab: Injection 105 mg in 1.17 mL single use pre-filled syringe; Evenity®
• Ruxolitinib: Tablet 5 mg, Tablet 10 mg; Jakavi®– September 2022 - November 2022
• Sapropterin: Tablet (soluble) containing sapropterin dihydrochloride 100 mg, Powder for oral solution 500 mg (as dihydrochloride); Kuvan®
• Trastuzumab deruxtecan: Powder for I.V infusion 100 mg; Enhertu® – July 2022 – December 2022- March 2023 – July 2023
• Upadacitinib: Tablet 15 mg, Tablet 30 mg, Tablet 45 mg; Rinvoq® - November 2022
• Ustekinumab (Ulcerative colitis): Injection 90 mg in 1 mL pre-filled syringe, Solution concentrate for I.V. infusion 130 mg in 26 mL; Stelara®
• Ustekinumab (Severe Crohn disease; Severe chronic plaque psoriasis): Injection 90 mg in 1 mL pre-filled syringe; Stelara®
• Vericiguat: Tablet 2.5 mg, Tablet 5 mg, Tablet 10 mg; Verquvo®
• Vosoritide: Powder for injection 0.4 mg with diluent, Powder for injection 0.56 mg with diluent, Powder for injection 1.2 mg with diluent; Voxzogo® – September 2022 - November 2022
• Review of base discount rate in the PBAC Guidelines